HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- methyl- 3- (1- (4- (piperazin- 1- yl)phenyl)- 5- (4'- (trifluoromethyl)- (1,1'- biphenyl)- 4- yl)- 1H- pyrazol- 3- yl)propanamide

inhibits integrin-linked kinase

Also Known As:

N-methyl-PPTBPP; OSU-T315

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide: 4
  - Piperazines: 26
    - N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-(1,1'-biphenyl)-4-yl)-1H-pyrazol-3-yl)propanamide: 4

Experts

1.	Chen, Chen: 1 article (10/2022)
2.	Fang, Kun: 1 article (10/2022)
3.	Li, Zhihui: 1 article (10/2022)
4.	Ren, Danhong: 1 article (10/2022)
5.	Sun, Leiming: 1 article (10/2022)
6.	Chen, Haifeng: 1 article (01/2022)
7.	Cheng, Mingming: 1 article (01/2022)
8.	Gao, Pengcheng: 1 article (01/2022)
9.	Li, Ganggang: 1 article (01/2022)
10.	Li, Hongrui: 1 article (01/2022)

Related Diseases

1.	Meningioma (Meningiomas) 01/01/2016 - "Our studies suggest that OSU-T315 has translational potential as a chemotherapeutic agent against VS and meningioma." 01/01/2016 - "OSU-T315 decreased cell viability at IC50 < 2μM in VS (HEI193) and meningioma (Ben-Men-1) cell lines, in primary cells at < 3.5μM, while in normal primary Schwann cells at 7.1μM. " 01/01/2016 - "The Novel Small Molecule Inhibitor, OSU-T315, Suppresses Vestibular Schwannoma and Meningioma Growth by Inhibiting PDK2 Function in the AKT Pathway Activation." 01/01/2016 - "Integrin-Linked Kinase (ILK) functions as PDK2 in PKB/AKT activation in many cancers; therefore, we hypothesized that OSU-T315, a small molecule ILK inhibitor, will inhibit the ILK-PDK2 function in PKB/AKT signaling activation in VS and meningioma cell growth. "
2.	Neoplasms (Cancer) 01/01/2022 - "In addition, the combination of OSU-T315 and GDC-0941 decreased p-AKT, p-S6, and p-p70S6K level, tumor volume, and tumor weight. " 01/01/2016 - "Integrin-Linked Kinase (ILK) functions as PDK2 in PKB/AKT activation in many cancers; therefore, we hypothesized that OSU-T315, a small molecule ILK inhibitor, will inhibit the ILK-PDK2 function in PKB/AKT signaling activation in VS and meningioma cell growth. "
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/08/2015 - "In this issue of Blood, Liu et al report on OSU-T315, a new agent that specifically disrupts the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway and shows high proapoptotic activity against chronic lymphocytic leukemia (CLL) cells, which may indicate a potential therapeutic application in this disease"
4.	Acoustic Neuroma (Acoustic Neurinoma) 01/01/2016 - "The Novel Small Molecule Inhibitor, OSU-T315, Suppresses Vestibular Schwannoma and Meningioma Growth by Inhibiting PDK2 Function in the AKT Pathway Activation."
5.	Breast Neoplasms (Breast Cancer) 01/01/2022 - "Breast cancer cell lines BT-474, MCF7, Hs-578-T, MDA-MB-231, MDA-MB-453, and MDA-MB-468 were cultured in different medium and then treated with 100 or 500 nM GDC-0941, 100 nM OSU-T315, or TNF-α antibody. "

Related Drugs and Biologics

1.	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
2.	Proto-Oncogene Proteins c-akt (Protein Kinase B)
3.	Doxorubicin (Adriamycin)
4.	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidine
5.	integrin-linked kinase